LCM
INO icon

Laurion Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Laurion Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,660
Closed -$51.8K – 569
2023
Q2 		$51.8K Buy
+9,660
New +$77.9K ﹤0.01% 562
2018
Q2 		– Sell
-2,058
Closed -$116K – 1438
2018
Q1 		$116K Buy
+2,058
New +$111K ﹤0.01% 1268

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Laurion Capital Management's INO Position: Q3 2023 in Review

Laurion Capital Management sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 9,660 shares — an estimated $51.8K sold.

Laurion Capital Management first reported a position in INO in Q1 2018 and held it in 2 quarters. The position peaked at $116K in Q1 2018. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.

  • Laurion Capital Management reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Laurion Capital Management sold 9,660 Inovio Pharmaceuticals shares in Q3 2023, an estimated $51.8K.
  • Laurion Capital Management first reported a position in Inovio Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Laurion Capital Management's Inovio Pharmaceuticals position peaked at $116K in Q1 2018.
  • 124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.